Published in Clinical Oncology Week, May 16th, 2005
Mundipharma is already SkyePharma's European marketing partner for the cancer treatment DepoCyte.
Under the agreement with Mundipharma, SkyePharma will receive $10 million on signature, most of which will be deferred and recognized to income to cover the cost of the phase 2 clinical trials. SkyePharma will also receive further contributions of up to US$20 million...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.